Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Lecture #10 Aims Describe T cell maturation and be able to differentiate naïve and effector T cells. Differentiate the development and functions of Th1.

Advertisements

B Cell Activation Abul K. Abbas UCSF FOCiS.

Activation of T Lymphocytes

B Cells and Antibodies Abul K. Abbas UCSF FOCiS.

Karl S. Peggs, Neil H. Segal, James P. Allison Cancer Cell

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Nat. Rev. Rheumatol. doi: /nrrheum

of different experimental arthritis models

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 5 Involvement of B cells in SLE

Figure 1 Structure of TNF antagonists

Figure 1 Induction of immune tolerance

Figure 2 Risk factors for sarcopenia

Figure 4 Simplified T cell and antigen presenting

Figure 1 Chimeric antigen receptor (CAR) structures

Figure 2 Heat map of targeted therapies in autoimmune diseases

The Leptin Connection: Regulatory T Cells and Autoimmunity

Figure 2 Main functions of IL-1

Figure 3 The T-cell cytokine tree in IBD

Figure 4 Involvement of SEMA4D in the pathogenesis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 3 TNFSF activities enhancing immune cell activation

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 2 Schematic representation illustrating the journey

Figure 3 Defects in the T cell receptor signalling pathway

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Figure 1 Activation and signalling of IL-1

Figure 2 Invariant natural killer T (iNKT) cells promote atherogenesis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Type 3 immunity and AS

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 3 Effect of sialylated glycoforms on IgG activity

Figure 1 Research advances in osteoarthritis management

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of biosimilar product development

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 3 LDL autoimmunity in atherosclerosis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 TNFSF inflammatory activities in tissue cells

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Current model of immunopathogenesis in CIDP

Figure 1 The current model of the pathogenesis of SLE

Langerhans Cells Orchestrate TFH-Dependent Humoral Immunity

Nat. Rev. Nephrol. doi: /nrneph

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Sequence of events in the development of autoimmune nephritis

Volume 143, Issue 1, Pages (July 2012)

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Cellular contributions to the development of SLE

Multistep Pathogenesis of Autoimmune Disease

Th1 and Th2 immune responses

Figure 1 The role of macrophages in RA

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Molecular signalling and immunological

Follicular Helper T Cells: Lineage and Location

Role of TACI during infection.

Figure 2 Involvement of plasmacytoid dendritic cells

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.158 Figure 3 B‑cell involvement in the immunopathogenesis of SLE and relevant therapeutic targets Figure 3 | B-cell involvement in the immunopathogenesis of SLE and relevant therapeutic targets. A key B-cell function is antigen presentation. Also, as B cells constitutively express both inhibitory and activating receptors, they can be simultaneously involved in immune activation as well as immunoregulatory functions (including their autoregulation by IL-10); the latter are independent of their antibody-dependent effector functions. By contrast, T cells can only upregulate inhibitory receptors after activation via antigen presentation. A number of potential therapeutic approaches target B cells, either via intrinsic B-cell functions or via their extrinsic interactions with other immune cells (Table 1 lists examples of targetable molecules). APC, antigen-presenting cell; GC, germinal centre; TFH, T follicular helper cell; TH1, T helper type 1 cell; TH17, T helper type 17 cell; BAFF-R, B-cell-activating factor receptor, also known as TNF receptor superfamily member 13C; TCR, T-cell receptor; BCR, B-cell receptor. Dörner, T. & Lipsky, P. E. (2016) Beyond pan‑B‑cell-directed therapy — new avenues and insights into the pathogenesis of SLE Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.158